Stockscreener 앱 받기
68.65
1.76%
-1.23
시간 외 거래:
68.65
전일 마감가:
$69.88
열려 있는:
$68.16
하루 거래량:
600.00K
Relative Volume:
0.59
시가총액:
$3.97B
수익:
$76.81M
순이익/손실:
$-162.42M
주가수익비율:
-22.96
EPS:
-2.99
순현금흐름:
$-122.49M
1주 성능:
+2.55%
1개월 성능:
+5.83%
6개월 성능:
-5.34%
1년 성능:
+8.43%
1일 변동 폭
$67.26
$69.99
1주일 범위
$66.12
$70.34
52주 변동 폭
$47.86
$94.07
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
68.65 | 4.04B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-22 | 개시 | Wells Fargo | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-03-07 | 개시 | Morgan Stanley | Overweight |
| 2024-01-04 | 재확인 | Needham | Buy |
| 2023-12-19 | 개시 | Scotiabank | Sector Outperform |
| 2023-10-30 | 개시 | TD Cowen | Outperform |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-05-18 | 개시 | Truist | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
| 2023-03-14 | 개시 | Stifel | Buy |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-13 | 재개 | BofA Securities | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-27 | 개시 | Needham | Buy |
| 2022-07-20 | 개시 | Canaccord Genuity | Buy |
| 2022-03-01 | 개시 | BofA Securities | Buy |
| 2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
Arcellx (NASDAQ:ACLX) Stock Rating Lowered by Rothschild & Co Redburn - MarketBeat
Rothschild Redburn downgrades Arcellx stock to Neutral on competition concerns By Investing.com - Investing.com South Africa
Rothschild Redburn downgrades Arcellx stock to Neutral on competition concerns - Investing.com India
FMR LLC Reduces Stake in Arcellx Inc: A Strategic Portfolio Adju - GuruFocus
(ACLX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Federated Hermes Inc. Cuts Position in Arcellx, Inc. $ACLX - MarketBeat
Arcellx stock maintains Buy rating at Stifel on promising safety data By Investing.com - Investing.com South Africa
Arcellx stock maintains Buy rating at Stifel on promising safety data - Investing.com
Weekly Earnings: Is Cytokinetics Incorporated stock a good pick for beginnersInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
Arcellx Director Sells 6,000 Shares for $450,000 - AOL.com
Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Does D-Domain CAR T Safety Data at Tandem 2026 Change The Bull Case For Arcellx (ACLX)? - simplywall.st
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Arcellx Inc (ACLX) and Align Tech (ALGN) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Align Tech (ALGN) and M3 (OtherMTHRF) - The Globe and Mail
Arcellx: Differentiated D-Domain BCMA CAR-T Profile and Safety Advantages Underpin Buy Rating and 58% Upside Potential - TipRanks
Arcellx (NASDAQ:ACLX) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Arcellx (ACLX): Needham Reiterates Buy Rating, Price Target at $105 | ACLX Stock News - GuruFocus
Arcellx reports D-Domain binder shows no tonic signaling in CAR T therapy - Investing.com Australia
Arcellx, Inc. Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder - marketscreener.com
Arcellx's Novel D-Domain Binder Accepted for Presentation at 2026 Tandem Meetings - Intellectia AI
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder - marketscreener.com
Arcellx lab study flags dual VHH off-target hits, D-Domain stays quiet - Stock Titan
Arcellx's (ACLX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Pathway Capital Management LP Takes $4.19 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Assessing Arcellx (ACLX) Valuation After Recent Share Price Swings And Conflicting P/B And DCF Signals - Yahoo Finance
Is Arcellx (ACLX) Still Attractively Priced After Strong Multi Year Share Price Gains - Yahoo Finance
Y Intercept Hong Kong Ltd Takes $1.27 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Liquidity Mapping Around (ACLX) Price Events - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX) - The Globe and Mail
Portfolio Shifts: What is Arcellx Incs valuation compared to sectorMarket Weekly Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect - Finviz
UBS initiates coverage of Arcellx with bullish outlook as biotech fundamentals inflect - MSN
11 Best High Short Interest Stocks With Biggest Upside Potential - Insider Monkey
Quarterly Risk: Can Arcellx Inc maintain sales growthQuarterly Profit Review & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Bond Watch: Can Arcellx Inc be the next market leaderJuly 2025 Sector Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Arcellx to present anito-cel data at 2026 Tandem Meetings By Investing.com - Investing.com Australia
Guggenheim Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $120 - 富途资讯
Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail
Legend Biotech, Arcellx rise after FDA draft guidance on multiple myeloma trials - MSN
Arcellx to present anito-cel data at 2026 Tandem Meetings - Investing.com
Arcellx study: earlier CAR T cut 5-year death risk by 48% - Stock Titan
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Why Arcellx Stock Is Sliding Despite Future Hopes - TipRanks
Arcellx director Lubner sells $450k in ACLX stock By Investing.com - Investing.com UK
Arcellx director Lubner sells $450k in ACLX stock - Investing.com
Why (ACLX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
FDA Guidance Boosts Arcellx (ACLX) and Legend Biotech (LEGN) Shares - GuruFocus
FDA Draft Guidance Boosts Arcellx (ACLX) and Legend Biotech (LEGN) Stock Prices - intellectia.ai
Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials - Seeking Alpha
Arcellx Stock Gains Momentum with New Buy Ratings - timothysykes.com
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):